ANVS
Annovis Bio
–
Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 37.49M; Volume: 65.73K; AvgVol 3m: 832.69K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.23; EPS growth quarter/prev quarter: -478.90%;
EPS growth this year: -20.20%; EPS growth past 5 years: ;
EPS ttm: -0.51;
P/S: ; P/B: 3.55; P/Cashflow: 3.48; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -55.40%; ROE – return on equity: -396.00%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 20.20%; Insider Transactions:0.00%;
Institutional Ownership: 11.10%; Institutional Transactions: 7.08%;
Data update: 07/10/2020.